Investors Hand Disc Medicine $90 Million to Control Hematological Diseases Published: Sept. 2, 2021 By Heather McKenzie BioSpace A two-year-old biopharma company tackling rare blood diseases has received a […]
The U.S. Food and Drug Administration approved Blueprint Medicines’ Ayvakit (avapritinib) for the treatment of adult patients with advanced systemic mastocytosis.
Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases, announced the completion of a $50 million Series A financing.
